Regeneron Beats Q2 Earnings Estimates on Dupixent Sales

Regeneron Pharmaceuticals reported strong second-quarter earnings and revenue that surpassed Wall Street estimates, driven by robust sales of its blockbuster eczema drug Dupixent, which rose 22% to $4.34 billion. Despite a 25% decline in U.S. sales of its eye disease drug Eylea, Regeneron’s overall revenue reached $3.68 billion, exceeding analyst expectations of $3.28 billion. The company also saw solid sales from its cancer treatment Libtayo and received FDA approval for Lynozyfic to treat multiple myeloma. Regeneron’s adjusted quarterly profit was $12.89 per share, significantly beating estimates and reflecting a 60.52% earnings surprise. While the company faces challenges such as competition impacting Eylea sales and regulatory delays at a manufacturing site, CEO Leonard Schleifer downplayed concerns about tariffs on EU imports. Additionally, Regeneron is among several drugmakers who received a letter from President Donald Trump urging them to reduce U.S. prescription drug prices to match overseas rates.